The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Constitutive Activation of NF-κB during Progression of Breast Cancer to Hormone-Independent Growth
Open accessAbstract
Breast cancers often progress from a hormone-dependent, nonmetastatic, antiestrogen-sensitive phenotype to a hormone-independent, antiestrogen- and chemotherapy-resistant phenotype with highly invasive and metastatic growth properties. This progression is usually accompanied by altered function of the estrogen receptor (ER) or outgrowth of ER-negative cancer cells. To understand the molecular mechanisms responsible for metastatic growth of ER-negative breast cancers, the activities of the transcription factor NF-kappaB (which modulates the expression of genes involved in cell proliferation, differentiation, apoptosis, and metastasis) were compared in ER-positive (MCF-7 and T47-D) and ER-negative (MDA-MB-231 and MDA-MB-435) human breast cancer cell lines. NF-kappaB, which is usually maintained in an inactive state by protein-protein interaction with inhibitor IkappaBs, was found to be constitutively active in ER-negative breast cancer cell lines. Constitutive DNA binding of NF-kappaB was also observed with extracts from ER-negative, poorly differentiated primary breast tumors. Progression of the rat mammary carcinoma cell line RM22-F5 from an ER-positive, nonmalignant phenotype (E phenotype) to an ER-negative, malignant phenotype (F phenotype) was also accompanied by constitutive activation of NF-kappaB. Analysis of individual subunits of NF-kappaB revealed that all ER-negative cell lines, including RM22-F5 cells of F phenotype, contain a unique 37-kDa protein which is antigenically related to the RelA subunit. Cell-type-specific differences in IkappaB alpha, -beta, and -gamma were also observed. In transient-transfection experiments, constitutive activity of an NF-kappaB-dependent promoter was observed in MDA-MB-231 and RM22-F5 cells of F phenotype, and this activity was efficiently repressed by cotransfected ER. Since ER inhibits the constitutive as well as inducible activation function of NF-kappaB in a dose-dependent manner, we propose that breast cancers that lack functional ER overexpress NF-kappaB-regulated genes. Furthermore, since recent data indicate that NF-kappaB protects cells from tumor necrosis factor alpha-, ionizing radiation-, and chemotherapeutic agent daunorubicin-mediated apoptosis, our results provide an explanation for chemotherapeutic resistance in ER-negative breast cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibodies, a laboratory manual
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90130-3 · Cited by 12,366
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Function and Activation of NF-kappaB in the Immune System
Baeuerle, P. A., & Henkel, T. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.001041 · Cited by 4,745
An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Beg, A. A., & Baltimore, D. (1996) · Science · doi:10.1126/science.274.5288.782 · Cited by 3,047
Baeuerle, P. A., & Baltimore, D. (1996) · Cell · doi:10.1016/s0092-8674(00)81318-5 · Cited by 3,001
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
Liotta, L. A., Steeg, P. S., & Stetler-Stevenson, W. G. (1991) · Cell · doi:10.1016/0092-8674(91)90642-c · Cited by 2,720
TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB
Wang, C.-Y., Mayo, M. W., & Baldwin, A. S. (1996) · Science · doi:10.1126/science.274.5288.784 · Cited by 2,617
Suppression of TNF-α-Induced Apoptosis by NF-κB
Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., & Verma, I. M. (1996) · Science · doi:10.1126/science.274.5288.787 · Cited by 2,581
Structure, Regulation and Function of NF-kappaB
Siebenlist, U., Franzoso, G., & Brown, K. (1994) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.10.110194.002201 · Cited by 2,075
Liu, Z.-G., Hsu, H., Goeddel, D. V., & Karin, M. (1996) · Cell · doi:10.1016/s0092-8674(00)81375-6 · Cited by 1,937
Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation.
Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van Antwerp, D., & Miyamoto, S. (1995) · Genes & Development · doi:10.1101/gad.9.22.2723 · Cited by 1,724
Brooks, P. C., Strömblad, S., Sanders, L. C., von Schalscha, T. L., Aimes, R. T., Stetler-Stevenson, W. G., Quigley, J. P., & Cheresh, D. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81235-0 · Cited by 1,552
Kastner, P., Krust, A., Turcotte, B., Stropp, U., Tora, L., Gronemeyer, H., & Chambon, P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08280.x · Cited by 1,534
Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB
Henkel, T., Machleidt, T., Alkalay, I., Krönke, M., Ben-Neriah, Y., & Baeuerle, P. A. (1993) · Nature · doi:10.1038/365182a0 · Cited by 1,104
IκB-β regulates the persistent response in a biphasic activation of NF-κB
Thompson, J. E., Phillips, R. J., Erdjument-Bromage, H., Tempst, P., & Ghosh, S. (1995) · Cell · doi:10.1016/0092-8674(95)90511-1 · Cited by 751
The value of estrogen and progesterone receptors in the treatment of breast cancer
Osborne, C. K., Yochmowitz, M. G., Knight, W. A., & McGuire, W. L. (1980) · Cancer · doi:10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u · Cited by 720
Repression of the Interleukin-6 Promoter by Estrogen Receptor Is Mediated by NF-κB and C/EBPβ
Stein, B., & Yang, M. X. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.9.4971 · Cited by 704
Sato, H., & Seiki, M. (1993) · PubMed · Cited by 695
Angel, P., Baumann, I., Stein, B., Delius, H., Rahmsdorf, H. J., & Herrlich, P. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.6.2256 · Cited by 694
Stein, B., Baldwin, A. S., Ballard, D. W., Greene, W. C., Angel, P., & Herrlich, P. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06066.x · Cited by 629
(1990) · PubMed · Cited by 612
Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells.
Wu, M., Lee, H., Bellas, R. E., Schauer, S. L., Arsura, M., Katz, D., FitzGerald, M. J., Rothstein, T. L., Sherr, D. H., & Sonenshein, G. E. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00845.x · Cited by 587
Thompson, E. W., Paik, S., Brünner, N., Sommers, C. L., Zugmaier, G., Clarke, R., Shima, T. B., Torri, J., Donahue, S., Lippman, M. E., et al. (1992) · Journal of Cellular Physiology · doi:10.1002/jcp.1041500314 · Cited by 523
Activation of the ovalbumin gene by the estrogen receptor involves the Fos-Jun complex
Gaub, M.-P., Bellard, M., Scheuer, I., Chambon, P., & Sassone-Corsi, P. (1990) · Cell · doi:10.1016/0092-8674(90)90422-b · Cited by 468
Gutman, A., & Wasylyk, B. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07394.x · Cited by 449
TGF-β1 inhibition of transin/stromelysin gene expression is mediated through a fos binding sequence
Kerr, L. D., Miller, D. B., & Matrisian, L. M. (1990) · Cell · doi:10.1016/0092-8674(90)90807-q · Cited by 439
Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis.
Nandi, S., Guzman, R. C., & Yang, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3650 · Cited by 422
The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties.
Tora, L., Mullick, A., Metzger, D., Ponglikitmongkol, M., Park, I., & Chambon, P. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03604.x · Cited by 417
Endocrine treatment of breast cancer in women
SANTEN, R. J., MANNI, A., HARVEY, H., & REDMOND, C. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-221 · Cited by 399 · cited 1×
“Numerous experimental and clinical studies have established that estrogen plays a major role in the initiation and progression of breast cancers (37, 44, 49).”
BackgroundBlasi, F. (1993) · BioEssays · doi:10.1002/bies.950150206 · Cited by 395
Wasylyk, C., Gutman, A., Nicholson, R., & Wasylyk, B. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb08053.x · Cited by 368
Negative Interaction between the RelA(p65) Subunit of NF-κB and the Progesterone Receptor
Kalkhoven, E., Wissink, S., van der Saag, P. T., & Burg, B. V. D. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.11.6217 · Cited by 352
Schulze-Osthoff, K., Krammer, P. H., & Dröge, W. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06780.x · Cited by 303
Ray, A., Prefontaine, K. E., & Ray, P. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99966-7 · Cited by 301
Johnston, S. R. D., Saccani‐Jotti, G., Smith, I. E., Salter, J., Newby, J. C., Coppen, M. J., Ebbs, S. R., & Dowsett, M. (1995) · PubMed · Cited by 301
Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report
Duffy, M. J., O'siorain, L., O'grady, P., Devaney, D., Fennelly, J. J., & Lijnen, H. J. (1988) · Cancer · doi:10.1002/1097-0142(19880801)62:3<531::aid-cncr2820620315>3.0.co;2-b · Cited by 282
Steroid receptors and other prognostic factors in primary breast cancer.
Clark, G. M., & McGuire, W. L. (1988) · PubMed · Cited by 271
Differentiation state and invasiveness of human breast cancer cell lines
Sommers, C. L., Byers, S. W., Thompson, E. W., Torri, J. A., & Gelmann, E. P. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666165 · Cited by 270
IκBγ, a 70 kd protein identical to the C-terminal half of p110 NF-κB: A new member of the IκB family
Inoue, J.-I., Kerr, L. D., Kakizuka, A., & Verma, I. M. (1992) · Cell · doi:10.1016/0092-8674(92)90082-n · Cited by 269
MINIREVIEW: Estrogen Receptor Variants in Clinical Breast Cancer
McGuire, W. L., Chamness, G. C., & Fuqua, S. A. W. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-11-1571 · Cited by 262
Higgins, K. A., Perez, J. R., Coleman, T. A., Dorshkind, K., McComas, W. A., Sarmiento, U. M., Rosen, C. A., & Narayanan, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.9901 · Cited by 261
Role of Unphosphorylated, Newly Synthesized IκBβ in Persistent Activation of NF-κB
Suyang, H., Phillips, R., Douglas, I., & Ghosh, S. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5444 · Cited by 221
Azzam, H. S., Arand, G., Lippman, M. E., & Thompson, E. W. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.21.1758 · Cited by 215
Ruben, S. M., Narayanan, R., Klement, J. F., Chen, C. H., & Rosen, C. A. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.2.444 · Cited by 170
Hansen, S. K., Nerlov, C., Zabel, U., Verde, P., Johnsen, M., Baeuerle, P. A., & Blasi, F. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05043.x · Cited by 168
Lykkesfeldt, A. E., Madsen, M. W., & Briand, P. (1994) · PubMed · Cited by 160
Nakshatri, H., & Chambon, P. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42196-x · Cited by 152
Self-citationNicholson, S., Wright, C., Sainsbury, J. R. C., et al. (1990) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(90)90424-j · Cited by 145
Galang, C. K., Garcı́a-Ramı́rez, J. J., Solski, P. A., Westwick, J. K., Der, C. J., Neznanov, N. S., Oshima, R. G., & Hauser, C. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.7992 · Cited by 127
Dejardin, E., Bonizzi, G., Bellahcène, A., Castronovo, V., Merville, M.-P., & Bours, V. (1995) · PubMed · Cited by 124
Variant Estrogen Receptor mRNA Species Detected in Human Breast Cancer Biopsy Samples
Murphy, L. C., & Dotzlaw, H. (1989) · Molecular Endocrinology · doi:10.1210/mend-3-4-687 · Cited by 107
Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor.
Russell, K., & Hung, M. (1992) · PubMed · Cited by 97
Tzukerman, M., Zhang, X.-K., & Pfahl, M. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-12-1983 · Cited by 95
Dumont, J. A., Bitonti, A. J., Wallace, C. D., et al. (1996) · PubMed · Cited by 89
Specific inhibition of RelB/p52 transcriptional activity by the C-terminal domain of p100.
Dobrzański, P., Ryseck, R.-P., & Bravo, R. (1995) · PubMed · Cited by 80
Yoza, B. K., Hu, J., & McCall, C. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18306 · Cited by 64
Mechanisms of hormone resistance in breast cancer
Horwitz, K. B. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00689685 · Cited by 64
Activation of the serum response factor by p65/NF‐kappaB.
Franzoso, G., Carlson, L. M., Brown, K., Daucher, M., Bressler, P. B., & Siebenlist, U. K. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00706.x · Cited by 63
Blasi, F. (1993) · Fibrinolysis and Proteolysis · doi:10.1016/0268-9499(93)90083-8 · Cited by 56
Lyle, R., Valleley, E. M. A., Sharpe, P. T., & Hewitt, J. (1994) · Gene · doi:10.1016/0378-1119(94)90823-0 · Cited by 13
Maxwell, S. A., & Mukhopadhyay, T. (1995) · Gene · doi:10.1016/0378-1119(95)00578-1 · Cited by 13
Cited by
NF-κB in cancer: from innocent bystander to major culprit
Karin, M., Cao, Y., Greten, F. R., & Li, Z.-W. (2002) · Nature Reviews Cancer · doi:10.1038/nrc780 · Cited by 2,478
Aggarwal, B. B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.003 · Cited by 1,574
Control of apoptosis by Rel/NF-κB transcription factors
Barkett, M., & Gilmore, T. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203238 · Cited by 1,204
Aberrant rel/nfkb genes and activity in human cancer
Rayet, B., & Gélinas, C. (1999) · Oncogene · doi:10.1038/sj.onc.1203221 · Cited by 1,110
Huber, M. A., Azoitei, N., Baumann, B., Grünert, S., Sommer, A., Pehamberger, H., Kraut, N., Beug, H., & Wirth, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421358 · Cited by 1,033
Metadata
- Authors
- Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J., & Sledge, G. W.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1997-07
- Volume
- 17
- Issue
- 7
- Pages
- 3629-3639
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2171865516
- Cited by
- 819
- References
- 61
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.